Radenkovic Sandra, Konjevic Gordana, Gavrilovic Dusica, Stojanovic-Rundic Suzana, Plesinac-Karapandzic Vesna, Stevanovic Predrag, Jurisic Vladimir
Institute of Oncology and Radiology of Serbia, Department of Radiation Oncology and Diagnostics, Belgrade, Serbia.
Institute of Oncology and Radiology of Serbia, Department of Radiation Oncology and Diagnostics, Belgrade, Serbia; Institute of Oncology and Radiology of Serbia, Department of Experimental Oncology, Serbia.
Pathol Res Pract. 2019 Feb;215(2):366-372. doi: 10.1016/j.prp.2018.12.023. Epub 2018 Dec 26.
Constitutive activation of STAT3 have been shown in several tumor types including breast cancer. We investigate STAT3 expresion as possible molecular marker for breast cancer early detection, as well as prognostic factor for determination of tumor agressiveness.
In this study we measure p(Y705)STAT3 expression in tumor and adjacent tissue of breast cancer patients by Western blot. For relapse-free survival (RFS) and overall survival (OS) we used Log-Rank test.
We show that average expression of p (Y705) STAT3 in tumor tissue is higher compared to adjacent tissue. Moreover, we found that patients with HER2 positive receptors had significantly higher pSTAT3 expression compared to HER2 negative patients. We showed that patients with high mammographic density had significantly higher tumor expression of pSTAT3 compared to patients with low mammographic density. Also, we show that pSTAT3 expression correlates with longer RFS in the entire group of patients, as well as in the group of ER positive, in lymph node positive and in older group of breast cancer patients (with age over 50). Furthermore, in the entire group of patients, in ER positive, in lymph node positive and in older group of patient, high expression of pSTAT3 showed a better survival than low expression of pSTAT3.
Considering that the expression of pSTAT3 is associated with longer RFS and survival, it can be used as prognostic tools for determination of group of breast cancer patients with low-risk.
STAT3的组成性激活已在包括乳腺癌在内的多种肿瘤类型中得到证实。我们研究STAT3表达作为乳腺癌早期检测的可能分子标志物，以及作为确定肿瘤侵袭性的预后因素。
在本研究中，我们通过蛋白质免疫印迹法测量乳腺癌患者肿瘤组织和相邻组织中p(Y705)STAT3的表达。对于无复发生存期（RFS）和总生存期（OS），我们使用对数秩检验。
我们发现肿瘤组织中p(Y705)STAT3的平均表达高于相邻组织。此外，我们发现HER2阳性受体患者的pSTAT3表达明显高于HER2阴性患者。我们还发现，乳腺X线密度高的患者肿瘤组织中pSTAT3的表达明显高于乳腺X线密度低的患者。同时，我们发现pSTAT3表达与整个患者组以及ER阳性、淋巴结阳性和年龄较大（50岁以上）的乳腺癌患者组的较长RFS相关。此外，在整个患者组、ER阳性、淋巴结阳性和年龄较大的患者组中，pSTAT3高表达患者的生存期优于pSTAT3低表达患者。
鉴于pSTAT3的表达与较长的RFS和生存期相关，它可作为确定低风险乳腺癌患者组的预后工具。
